Hepatitis B control: country profile 2020

HepaƟƟs B Control Country Profile 2020 WHO/Daniel Hodgson

Country Profile 2020 © World Health Organization 2021 ISBN 978 92 9061 698 6 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html). For WHO Western Pacific Regional Publications, request for permission to reproduce should be addressed to Publications Office, World Health Organization, Regional Office for the Western Pacific, P.O. Box 2932, 1000, Manila, Philippines, fax: +632 8521 1036, email: publications@wpro.who.int The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Cover photo: WHO CONTENTS Country Profiles American Samoa 3 Australia 4 Brunei Darussalam 5 Cambodia 6 China 7 China, Hong Kong SAR 8 China, Macao SAR 9 Cook Islands 10 Fiji 11 French Polynesia 12 Guam 13 Japan 14 Kiribati 15 Lao People’s Democratic Republic 16 Malaysia 17 Marshall Islands 18 Micronesia (Federated States of) 19 Mongolia 20 Nauru 21 New Caledonia 22 New Zealand 23 Niue 24 Northern Mariana Islands, Commonwealth of the 25 Palau 26 Papua New Guinea 27 Philippines 28 Republic of Korea 29 Samoa 30 Singapore 31 Solomon Islands 32 Tokelau 33 Tonga 34 Tuvalu 35 Vanuatu 36 Viet Nam 37 Wallis and Futuna 38 Regional Progress: Hepatitis B Vaccination Coverage, 1990—2020 1 Regional Progress: Status of the 2020 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children 2 Regional Progress Hepatitis B vaccination coverage, 1990 – 2020 Source: WHO and UNICEF Joint Reporting Form on Immunization Regional coverage is based on calculated average among all countries, whether they reported coverage or not 1 Regional Progress as of December 2020 Status of the 2020 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO Regional Office for the Western Pacific 2020. All rights reserved 2 <1% Verified (21) <1% but not verified (5) >1% (9) or no data (1) Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 3 AMERICAN SAMOA Total population (2020) 55 197 Births (2011) 1 287 Surviving infants (2011) 1 278 Urban population (2020) 90% HepB3 introduced nationwide 1986-1987 HepB birth dose introduced 1991 Current schedule 0, 1 month, 12 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1990 National 3–4 years 95 not reported 82% not reported Mahoney Pac Hth Dialog 1996 1995 National 7-8 years 432 75% 91% not reported Bialek ISVHLD P351 2006 1996 National 7-8 years 435 not reported 87% not reported Mahoney Pac Hth Dialog 1996 2016 National 24-35 months 1180 97% 82% 85% MMWR May 25, 2018 / 67(20);579–584 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1991 Tutuila 3-4 years Community based 93 2.2% Mahoney JID 2009 1995 National 7-8 years Community based 432 0.5% Bialek ISVHLD P351 2006 2011 National 6 years School based 562 0.2% Govt American Samoa 2012 Status of verifying prevalence targets Verification started: February 2013 Decision: <1% in children Decision date: October 2014 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 4 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification AUSTRALIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2007 National 12 months 280 874 not reported 94% 92% From National Health Insurance covering 99% of population Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2002 National 1-9 years Hospital based 249 0.4% (0.0% - 2.2%) Gidding Vaccine 2007 Total population (2020) 25 499 881 Births (2020) 318 478 Surviving infants (2020) 317 554 Urban population (2020) 86% HepB3 introduced nationwide 2000 HepB birth dose introduced 2000 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-Hib-HepB-IPV Verification started: June 2012 Decision: <1% in children Decision date: December 2012 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF’s Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank’s World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t s HepB3 Timely HepB BD * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 5 BRUNEI DARUSSALAM Total population (2020) 437 483 Births (2020) 6 156 Surviving infants (2020) 6 110 Urban population (2020) 80% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-Hib-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2011 National 8-9 years School based 4 513 0.09% MoH Brunei 2012 Status of verifying prevalence targets Verification started: March 2013 Decision: <1% in children Decision date: June 2013 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * 6 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification CAMBODIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2005 National 12-23 months 1517 not reported not reported 78% DHS Survey 2009 National 12-23 months 1068 61% not reported 56% Cambodia Socio-Economic Survey 2009 (confirmation method only by card) 2010 National 12-23 months 1614 73% 84% 84% DHS Survey:HepB BD 73%, HepB3 85%, DTP3 85% by 12 months 2014 National 12-23 months 1460 83% 84% 84% DHS Survey:HepB BD 83%, HepB3 82%, DTP3 82% by 12 months Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2001 Kg Chhnang 9-17 months Hospital based 900 2.7% Report MoH/PATH/AIHI 2006 National 5 years Community based 1 558 3.5% (2.4% - 4.8%) Soeung AMTH 2009 2011 Urban, Rural, Remote 4-5 years Community based 2 429 0.3%, 1.4%, 3.5% Mao Vaccine 2013 2017 National 5-6 years Community based 2 520 0.6% (0.3% - 1.0%) Cambodia MOH 2017 preliminary data 2017 National 5-7 years Cross-sectional survey 2 520 0.56% Ork Vaccine 2019 Total population (2020) 16 718 971 Births (2020) 360 189 Surviving infants (2020) 352 521 Urban population (2020) 24% HepB3 introduced nationwide 2005 HepB birth dose introduced 2005 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Verification started: January 2018 Decision: <1% in children Decision date: June 2018 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 7 CHINA Total population (2020) 1 439 323 774 Births (2020) 16 233 446 Surviving infants (2020) 16 086 657 Urban population (2020) 61% HepB3 introduced nationwide 1992 HepB birth dose introduced 1992 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2004 National 12-23 months 171 188 not reported 85% not reported The National EPI Evaluation Report 2004 (Confirmation method by card only); 90% HepB3 by 12 months 2006 National 1 year 3636 93% 83% not reported Liang JID 2009; 2005 birth cohort 2008 National 12-23 months 9762 not reported 93% 91% Analysis Report of National Health Services Survey in China Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2006 National 1-4 years Community based 16 376 1.0% (0.8% - 1.2%) Liang JID 2009 2006 National 5 years Community based 2215 1.1% (0.4% - 1.8%) Liang JID 2009 2006 National 6 years Community based 2356 0.9% (0.4% - 1.5%) Liang JID 2009 2012 National 1-4 years Community based 5474 0.5% (0.3% - 0.7%) Yonghao International Journal of Infectious Diseases 2015 2012 National 5-9 years Community based 4407 0.7% (0.5% - 1.0%) Yonghao International Journal of Infectious Diseases 2015 2012 National 10-14 years Community based 3326 1.2% (0.8% - 1.6%) Yonghao International Journal of Infectious Diseases 2015 2014 National 1-4 years Community based 12 681 0.3% (0.2% - 0.5%) Cui FQ Emerging Infectious Diseases 2017 2014 National 5-14 years Community based 9738 0.9% (0.7% - 1.3%) Cui FQ Emerging Infectious Diseases 2017 2014 National 15-29 years Community based 9294 4.4% (3.8% - 5.1%) Cui FQ Emerging Infectious Diseases 2017 Status of verifying prevalence targets Verification started: February 2012 Decision: <1% in children Decision date: June 2012 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. Hepatitis B serological surveys 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * 8 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification HONG KONG SAR (CHINA) Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2009 National 2-5 years 6248 not reported ≥99.5% >99.8% MoH Hong Kong 2011 2015 National 2-5 years not reported >95.0% >95.0% >95.0% WHO-UNICEF Joint Reporting Form (data for 2017) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2006 National 1-4 years Laboratory based 196 1% MoH Hong Kong 2011 2009 National 12-15 years School based 1913 0.8% (0.4% - 1.2%) MoH Hong Kong 2011 Total population (2020) 7 496 988 Births (2020) 82 839 Surviving infants (2020) 82 736 Urban population (2020) 100% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Verification started: February 2011 Decision: <1% in children Decision date: July 2011 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 9 MACAO SAR (CHINA) Total population (2020) 649 342 Births (2020) 6 961 Surviving infants (2019) 6 944 Urban population (2020) 100% HepB3 introduced nationwide 1984 HepB birth dose introduced 1989 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2003 National 6-9 years School based 437 0% (0% - 0.7%) MoH Macao 2008 Status of verifying prevalence targets Verification started: April 2008 Decision: <1% in children Decision date: August 2008 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD 10 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification COOK ISLANDS Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2012 7 of 11 islands 6 years School based 269 0% Patel Vaccine 2016 Total population (2020) 17 564 Births (2019) 218 Surviving infants (2019) 218 Urban population (2020) 75% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 6 weeks, 3 months, 5 months HepB3 type DTP-Hib-HepB Verification started: January 2013 Decision: <1% in children Decision date: October 2013 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 11 FIJI Total population (2020) 896 444 Births (2020) 18 472 Surviving infants (2020) 18 112 Urban population (2020) 59% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1999 National 12-23 months not reported not reported 94% 92% Fiji National EPI Survey 2005 National 12-23 months 630 not reported 92% 83% Fiji Immunization Coverage Survey Report 2008 National 15-26 months 1200 86% 99% 99% Fiji National Immunisation Coverage Survey 2013 National not reported not reported not reported not reported 91% WHO-UNICEF Joint Reporting Form (Data for 2014) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998 Large Towns 12-24 months Hospital based 285 0.7% Wilson Vaccine 2000 2008 Sub-national 6 months-5 years Community based 428 0% WHO:RS/2009/GE/23(JPN) Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization HepB3 coverage at national and district level are inconsistent due to different data sources used by Fiji. *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * 12 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification FRENCH POLYNESIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1988 Austral Island 0-11 months Community based 957 2.1% B Trans R Soc Trop 1990 2013-2014 National 6-7 years School based 1196 0.0% (0.0%-0.5%) Patel Vaccine 2016 Total population (2020) 280 904 Births (2020) 3 983 Surviving infants (2020) 3 958 Urban population (2020) 64% HepB3 introduced nationwide 1992 HepB birth dose introduced 1992 Current schedule 0, 2 months, 10 months HepB3 type DTP-Hib-HepB-IPV Verification started: February 2016 Decision: <1% in children Decision date: September 2016 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 13 GUAM Total population (2020) 168 783 Births (2020) 2 756 Surviving infants (2020) 2 734 Urban population (2020) 95% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 1-2 months, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2015 National 6 years School based 1484 0.0% Guam DoH & Social Services 2015 Status of verifying prevalence targets Verification started: October 2015 Decision: <1% in children Decision date: June 2016 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD 14 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification JAPAN Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1989 Okinawa 1-4 years School based 1529 0.1% Hayashi Int J Epi 1990 1995-1996 National 16-19 years Blood Donors 107 879 0.4% (0.4% - 0.5%) Furusyo AMTM 1998 1995-2000 National 16-19 years Blood Donors 582 415 0.23% (0.22% - 0.24%) Tanaka Intervirol 2004 2009 Iwate prefecture 5-9 years School based 17 363 0.0% (0.00%-0.04%) Tanaka Intervirol 2011 2005-2010 National 4-15 years Serum reference bank 3000 0.17% (0.0-0.41) Kiyohara T Vaccine 2015 Total population (2020) 126 476 458 Births (2020) 908 919 Surviving infants (2020) 907 427 Urban population (2020) 92% HepB3 introduced nationwide October 2016 HepB birth dose introduced If born to HBsAg+ mothers Current schedule 2 months, 3 months, 7 months HepB3 type Monovalent Verification started: pending Decision: n.a. Decision date: n.a. Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 15 KIRIBATI Total population (2020) 119 446 Births (2020) 3 233 Surviving infants (2020) 3 104 Urban population (2020) 57% HepB3 introduced nationwide 1995 HepB birth dose introduced 1990 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2009 National 48-59 months 181 not reported not reported 32% DHS Survey; by 12 months 2009 National 36-47 months 200 not reported not reported 42% DHS Survey; by 12 months 2009 National 24-35 months 202 not reported not reported 50% DHS Survey; by 12 months 2009 National 12-23 months 233 not reported 61% 61% DHS Survey: HepB3 58%, DTP3 58% by 12 months Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998 Large Towns 12-24 months Hospital based 156 3.8% Wilson Vaccine 2000 2014 National 5-9 years Community based 1249 3.3% (2.4% - 4.6%) Patel Vaccine 2016 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * 16 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification LAO PEOPLE’S DEMOCRATIC REPUBLIC Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2006 National 12-23 months 828 not reported not reported 41% Lao PDR Multiple Indicator Cluster Survey 2006 Final Report; DTP3 32% by 12 months 2011-2012 National 12-23 months 2141 37% 56% 56% Lao Social Indicator Survey (LSIS), (MICS / DHS Survey): HepB BD 37%, HepB3 52%, DTP3 52% by 12 months 2015 National 12-23 months 5981 72% 81% 81% National Immunization Survey Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2012 National 5-9 years Community based 965 1.7% (0.8% - 2.6%) Xeuatvongsa PloS ONE 2014 Total population (2020) 7 275 556 Births (2020) 164 753 Surviving infants (2020) 158 882 Urban population (2020) 36% HepB3 introduced nationwide 2001 HepB birth dose introduced ~2004 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Verification started: pending Decision: n.a. Decision date: n.a. Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 17 MALAYSIA Total population (2020) 32 365 998 Births (2020) 531 804 Surviving infants (2020) 528 868 Urban population (2020) 78% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1997-2007 National 6-9 years School based 193 717 0.40% MoH Malaysia 2011 2003 National 7 years School based 12 269 0.40% Ng Med Microb Imm 2005 2007 National 7-9 years Community based 1735 0.30% MoH Malaysia 2008 2009 National 9 years School based 2938 0.2% (0% - 0.3%) MoH Malaysia 2011 2009 National 10 years School based 3265 0.4% (0.2% - 0.6%) MoH Malaysia 2011 Status of verifying prevalence targets Verification started: March 2011 Decision: <1% in children Decision date: July 2011 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * 18 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification MARSHALL ISLANDS Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2006 National 0-24 months 115 not reported 86% 65% RMI Community Survey2006: confirmation method by card only 2007 Majuro, Ebeye 5-9 years 331 49% 93% not reported Bialek Ped Infect Dis 2010 2007 National not reported 214 not reported not reported 17% (for age 48-59M); 32% (for age 36-47M) DHS Survey 2007: DTP3 by 12 months 2007 National 24-35 months 207 not reported not reported 32% DHS Survey 2007: DTP3 by 12 months 2007 National 12-23 months 249 not reported not reported 48% DHS Survey; DTP3 38% by 12 months 2016 National 24-35 months 1312 87% 76% 72% MMWR May 25, 2018 / 67(20);579–584 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2007 Majuro, Ebeye 5-9 years School based 331 1.8% (0.4% - 3.3%) Bialek PID 2010 2016 National 5-6 years School based 1148 1.2% (0.6% - 1.9%) 2018 MoH Marshall Islands Total population (2020) 59 194 Births (2019) 1 090 Surviving infants (2019) 1 068 Urban population (2020) 70% HepB3 introduced nationwide 1990s HepB birth dose introduced 1998 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-HepB-IPV Verification started: pending Decision: n.a. Decision date: n.a. Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 19 FEDERATED STATES OF MICRONESIA Total population (2020) 115 021 Births (2020) 2 601 Surviving infants (2020) 2 544 Urban population (2020) 21% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1989 National 2 years 16 391 not reported 84% not reported Manea PH Reports 1992 1992 Chuuk 2 years 544 not reported 40% not reported Mahoney Pac Hth Dialog 1996 1994 Pohnpei 3-4 years 364 not reported 82% not reported Mahoney Pac Hth Dialog 1996 2000 Chuuk 2-6 years 365 50% 87% not reported Bialek ISVHLD P351 2006 2005 Pohnpei 2-9 years 478 87% 90% not reported Bialek Ped Infect Dis 2010 2005 National 2-9 years 432 75% 91% not reported Bialek ISVHLD P351 2006 2016 Chuuk 24-25 months 1218 54% 78% 72% MMWR May 25, 2018 / 67(20);579–584 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2005 Chuuk 2-6 years Hospital based 362 2.5% Bialek PID 2010 2005 Pohnpei 2-6 years Hospital based 478 1.5% Bialek PID 2010 2016 National 5-6 years School based 2106 0.3% (0.1% - 0.5%) 2017 MoH Federated States of Micronesia Status of verifying prevalence targets Verification started: October 2017 Decision: <1% in children Decision date: March 2018 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. Hepatitis B serological surveys 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * 20 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2001 National 12-23 months 1255 not reported not reported 89% Mongolia, Child and Development survey-2000 (MICS-2), 2001 2004 National 4-6 years 5894 95% 73% not reported MoH Mongolia 2011 2004 National 8 years 1145 65% 60% not reported Davaalkham J Epid 2007 2005 National 12-23 months 724 not reported not reported 93% Mongolia Child and Development 2005 Survey (MICS-3): DTP3-92% by 12M 2010 National 12-23 months 944 97% not reported 92% MICS : HepB BD 96.7% by 12M; DPT3 92.1% by 12M 2013 National 12-23 months 1180 99% 98% 98% Mongolia Social Indicator Sample Survey: HepB BD 93.1%, HepB3 92.5%, DTP3 92.5% by 12M 2013 National 24-35 months 1236 97% 96% 96% Mongolia Social Indicator Sample Survey :HepB BD 86%, HepB3 84.2%, DTP3 84.2% by 12M Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2004 National 7-12 years School based 1145 5.2% Davaalkham PI 2007 2009 National 4 years Community based 5894 0.5% MoH Mongolia 2011 Total population (2020) 3 278 292 Births (2020) 73 755 Surviving infants (2020) 72 552 Urban population (2020) 67% HepB3 introduced nationwide 1991 HepB birth dose introduced 1991 Current schedule 0, 2 months, 3 months, 4 months HepB3 type DTP-Hib-HepB Verification started: April 2012 Decision: <1% in children Decision date: July 2012 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. MONGOLIA 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 21 NAURU Total population (2020) 10 834 Births (2019) 335 Surviving infants (2019) 326 Urban population (2020) 100% HepB3 introduced nationwide 1983 HepB birth dose introduced Yes, introduction year unknown Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD 22 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification NEW CALEDONIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes Total population (2020) 285 491 Births (2020) 3 938 Surviving infants (2020) 3 895 Urban population (2020) 72% HepB3 introduced nationwide 1989 HepB birth dose introduced Yes, introduction year unknown Current schedule 0, 2 months, 11 months HepB3 type DTP-Hib-HepB-IPV Verification started: pending Decision: n.a. Decision date: n.a. Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 23 NEW ZEALAND Total population (2020) 4 822 233 Births (2020) 59 671 Surviving infants (2020) 59 459 Urban population (2020) 87% HepB3 introduced nationwide 1985 HepB birth dose introduced If born to HBsAg+ mothers Current schedule 6 weeks, 3 months, 5 months HepB3 type DTP-Hib-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2005 National 12 months 1563 72% 82% 85% MoH; 87% HepB3 by 2 years Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2009 North Islands 6 years Health facility 466 0.2% (0.0% - 1.2%) Weir R. MoH New Zealand 2009 Status of verifying prevalence targets Verification started: April 2012 Decision: <1% in children Decision date: September 2012 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF’s Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank’s World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * 24 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification NIUE Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2015 National 5-12 years School based 183 0.0% Patel Vaccine 2016 Total population (2020) 1 618 Births (2019) 23 Surviving infants (2019) 23 Urban population (2020) 47% HepB3 introduced nationwide 1986 HepB birth dose introduced Yes, introduction year unknown Current schedule 0, 6 weeks, 3 months, 5 months HepB3 type DTP-Hib-HepB-IPV Verification started: November 2015 Decision: <1% in children Decision date: February 2017 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 25 NORTHERN MARIANA ISLANDS, COMMONWEALTH OF THE Total population (2020) 57 557 Births (2019) 909 Surviving infants (2019) 905 Urban population (2020) 88% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 6 weeks, 4 months, 6 months HepB3 type DTP-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1995 National 3-4 years 200 not reported 94% not reported Mahoney Pac Hth Dialog 1996 2005 National 19-35 months 295 100% 94% not reported 2016 National 24-35 months 1140 98% 62% 60% MMWR May 25, 2018 / 67(20);579–584 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1994 Saipan 3-4 years Health facility 200 0.5% Durand Pac Hlth Dial 1996 2014 National 6 years School based 804 0.0% CNMI Healthcare Corp. 2015 Status of verifying prevalence targets Verification started: December 2015 Decision: <1% in children Decision date: April 2017 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD 26 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification PALAU Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2003 National 10-11 years 192 100% 85% not reported Bialek ISVHLD P351 2006 2016 National 24-35 months 259 97% 93% 95% MMWR May 25, 2018 / 67(20);579–584 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2003 National 10-11 years Community based 192 0% Bialek ISVHLD P351 2006 2008 Main Island 5-7 years School based 143 0% MoH Palau 2013 Total population (2020) 18 092 Births (2019) 213 Surviving infants (2019) 209 Urban population (2020) 100% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 2 months, 6 months HepB3 type DTP-HepB-IPV Verification started: January 2013 Decision: <1% in children Decision date: May 2013 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 27 PAPUA NEW GUINEA Total population (2020) 8 947 027 Births (2020) 237 474 Surviving infants (2020) 228 176 Urban population (2020) 13% HepB3 introduced nationwide 1989 HepB birth dose introduced ~2003 Current schedule 0, 1 month, 2 months, 3 months HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2005-2006 National 12-23 months 2137 not reported 65% 67% National Immunization Coverage Survey Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1989-1990 Port Moresby 3-5 months Hospital Based 31 13% Nemba ATPaed. 1993 2012-2013 National 4-6 years Community based 2109 2.3% Kitau ASTMH 2015 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * 28 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification PHILIPPINES Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1998-1999 National 12-23 months 1474 not reported not reported 81% DHS Survey: DTP3 79% by 12 months 2000 National 12-23 months 2227 not reported 32% 80% Philippines, Maternal and Child Health Survey 2000 2002 National 12-23 months 1885 not reported not reported 81% Philippines, Maternal and Child Health Survey 2002 2003 National 12-23 months 1348 not reported not reported 79% DHS Survey: DTP3 75% by 12 months 2008 National 12-23 months 1286 not reported 80% 86% DHS Survey (NDHS) 2008: by 12 months (HepB3 76%, DTP3 83%) 2013 National 12-23 months 1397 not reported 78% 86% DHS Survey, 2013: by 12 months (HepB3 74%, DTP3 85%) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2018 National 5-7 years Household survey 2 178 0.8% Minta PubMed 2021 Total population (2020) 109 581 085 Births (2020) 2 182 501 Surviving infants (2020) 2 142 391 Urban population (2020) 47% HepB3 introduced nationwide 1991 HepB birth dose introduced 2007 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Verification started: pending Decision: n.a. Decision date: n.a. Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 29 REPUBLIC OF KOREA Total population (2020) 51 269 183 Births (2020) 358 793 Surviving infants (2020) 358 115 Urban population (2020) 82% HepB3 introduced nationwide 1983 HepB birth dose introduced 1983 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2008 National 0-6 years 1026 100% 93% 95% CDC Korea; provided during 2012 TAG 2009 National 19-35 months not reported not reported 99% 99% 2009 Korea National Immunization Survey (Confirmation method NA) 2011 National 0-3 years 7040 99% 98% 93% CDC Korea; provided during 2012 TAG Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2005 National 10-14 years Community based 594 0.2% (0.0% - 0.6%) CDC Korea 2008 2007 National 4-6 years Hospital based 2920 0.2% (0.0% - 0.4%) CDC Korea 2008 2014 National 10-18 years Community based 510 0.1% KNHANES 2014 Status of verifying prevalence targets Verification started: January 2008 Decision: <1% in children Decision date: June 2008 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD 30 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification SAMOA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2009 National 12-24 months 321 70% not reported not reported DHS Survey 2009 National 18-29 months 321 not reported not reported 38% DHS Survey:37% DTP3 by 12 months 2014 National 48-59 months 559 75% 45% 45% DHS Survey; by 12 months 2014 National 36-47 months 605 81% 50% 50% DHS Survey; by 12 months 2014 National 24-35 months 680 82% 54% 54% DHS Survey; by 12 months 2015 National 12-23 months 674 84% 64% 64% DHS Survey; by 12 months 2015 National 18-29 months 666 83% 64% 64% DHS Survey; by 18 months 83% HepB, 63% HepB3 and 63% DTP3 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2014 National 5-6 years School based 1776 0.11% MoH Samoa 2015 Total population (2020) 198 410 Births (2020) 4 761 Surviving infants (2020) 4 701 Urban population (2020) 18% HepB3 introduced nationwide 1990 HepB birth dose introduced Yes, introduction year unknown Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Verification started: pending Decision: n.a. Decision date: n.a. Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 31 SINGAPORE Total population (2020) 5 850 343 Births (2020) 49 976 Surviving infants (2020) 49 901 Urban population (2020) 100% HepB3 introduced nationwide 1985 HepB birth dose introduced 1987 Current schedule 0, 1 month, 5-6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2007 National 2 years 31 778 not reported 94%-96% 97% Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998-1999 National 0-4 years not reported 229 0% Epi News Bull SNG 2000 2008-2010 Two public hospitals 1-17 years Hospital based 1200 0.3% (0.1%-0.9%) Ang J Med Virol 2013 Status of verifying prevalence targets Verification started: April 2015 Decision: <1% in children Decision date: October 2015 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF’s Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank’s World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD 32 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification SOLOMON ISLANDS Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2006-2007 National 48-59 months 477 not reported not reported 72% DHS Survey (DTP3 by 12 months) 2006-2007 National 36-47 months 515 not reported not reported 81% DHS Survey (DTP3 by 12 months) 2006-2007 National 24-35 months 533 not reported not reported 80% DHS Survey (DTP3 by 12 months) 2006-2007 National 12-23 months 535 not reported not reported 88% DHS Survey (87% DTP3 by 12 months) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1999 Guadalcanal Islands 0-9 years Hospital based 115 13% Furusyo Am J Trop 1999 2016 National 6-7 years School based 1 169 3.1% (2.0% - 4.9%) Breakwell Vaccine 2020 Total population (2020) 686 878 Births (2020) 21 589 Surviving infants (2020) 21 277 Urban population (2020) 23% HepB3 introduced nationwide 1990 HepB birth dose introduced ~2005 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB Verification started: pending Decision: n.a. Decision date: n.a. Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 33 TOKELAU Total population (2020) 1 350 Births (2020) 35 Surviving infants (2020) 28 Urban population (2020) 0% HepB3 introduced nationwide 1990 HepB birth dose introduced 1990 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2014 National 6-12 years School based 171 0.0% Patel Vaccine 2016 Status of verifying prevalence targets Verification started: May 2015 Decision: <1% in children Decision date: June 2016 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * 34 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification TONGA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2003 National 12-23 months 114 not reported 94% 96% Evaluation of Immunization Program of the Kingdom of Tonga 2005 Tongatapu hospital 6-59 months 445 92% 98% 98% Danielsson Vaccine 2009 2012 National 48-59 months 302 not reported 61% 61% DHS Survey (HepB3 and DTP3 by 12 months) 2012 National 36-47 months 334 not reported 59% 59% DHS Survey (HepB3 and DTP3 by 12 months) 2012 National 24-35 months 383 not reported 60% 60% DHS Survey (HepB3 and DTP3 by 12 months) 2012 National 12-23 months 307 not reported 66% 66% DHS Survey (65% HepB3 and 65% DTP3 by 12 months) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998 Large Towns 12-24 months Hospital based 211 3.8% Wilson Vaccine 2000 2005 Main Island 6-59 months Hospital based 375 0.8% (0.2% - 2.5%) Danielsson Vaccine 2009 Total population (2020) 105 697 Births (2020) 2 502 Surviving infants (2020) 2 473 Urban population (2020) 24% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB Verification started: May 2011 Decision: <2% in children Decision date: January 2012 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 35 TUVALU Total population (2020) 11 792 Births (2019) 307 Surviving infants (2019) 307 Urban population (2020) 62% HepB3 introduced nationwide Yes, introduction year unknown HepB birth dose introduced Yes, introduction year unknown Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2007 National 48-59 months 75 not reported not reported 59% DHS Survey (DTP3 by 18 months) 2007 National 36-47 months 84 not reported not reported 57% DHS Survey (DTP3 by 18 months) 2007 National 24-35 months 89 not reported not reported 60% DHS Survey (DTP3 by 18 months) 2007 National 18-29 months 80 not reported not reported 62% DHS Survey (60% DTP3 by 18 months) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1976 Fanafuti 10-19 years Community based 181 11% Gust JID 1979 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * 36 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification VANUATU Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2007 National 12-23 months 359 not reported 59% 63% MICS; by 12 months 55% HepB3, 58% DTP3 2013 National 12-23 months 303 not reported 55% 55% DHS Survey; by 12 months 49% HepB3, 49% DTP3 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1988 Emao or Nguna 12-18 months Community based 112 17% Maher Med J Aust 1991 1998 Large Towns 12-24 months Hospital based 132 3.0% Wilson Vaccine 2000 Total population (2020) 307 150 Births (2020) 8 838 Surviving infants (2020) 8 654 Urban population (2020) 24% HepB3 introduced nationwide 1989–1990 HepB birth dose introduced 1989–1990 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB Verification started: pending Decision: n.a. Decision date: n.a. Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 37 VIET NAM Total population (2020) 97 338 583 Births (2020) 1 566 556 Surviving infants (2020) 1 541 383 Urban population (2020) 38% HepB3 introduced nationwide 1997 HepB birth dose introduced 2005 Current schedule 0, 2 months, 3 months, 4 months HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2002 National 12-24 months 457 not reported not reported 72% DHS Survey 2006 National 12-23 months 555 not reported 34% 79% MICS; 32% HepB3 and 76% DTP3 by 12 months 2002-2003 National 12-23 months 457 not reported not reported 72% DHS Survey 2010-2011 National 12-23 months 759 not reported 56% 74% MICS; 53% HepB3 and 73% DTP3 by 12 months 2014 National 24-35 months 641 71% 92% 93% MICS; 71% HepB BD, 92% HepB3 and 93% DTP3 by 12 months 2014 National 12-23 months 790 78% 87% 89% MICS; 78% HepB BD, 87% HepB3 and 89% DTP3 by 12 months 2015 National 12-23 months 2417 56% 98% 85% WHO-UNICEF Joint Reporting Form (data for 2017) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998 Thanh Hoa 9-18 months Community based 536 12.5% Hipgrave AJTMH 2003 2011 National 3-4 years Community based 3426 1.6% (1.25%-2.15%) Nguyen Vaccine 2014 2011 National 5-7 years Community based 1738 2.2% (1.47%-3.14%) Nguyen Vaccine 2014 2011 National 8-11 years Community based 1740 3.6% (2.80%-4.71%) Nguyen Vaccine 2014 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD * 38 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification WALLIS AND FUTUNA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2011 National 7-12 years 442 not reported 94% not reported Data from national serosurvey Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2012 National 9-11 years School-based 428 0.93% Preliminary data Total population (2020) 11 246 Births (2019) 147 Surviving infants (2019) 146 Urban population (2020) 0% HepB3 introduced nationwide Yes, introduction year unknown HepB birth dose introduced Yes, introduction year unknown Current schedule 0, 2 months, 11 months HepB3 type DTP-Hib-HepB-IPV Verification started: pending Decision: n.a. Decision date: n.a. Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2017 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD

Vaccine‐Preventable Diseases and ImmunizaƟon Regional Office for the Western Pacific World Health OrganizaƟon P.O. Box 2932, 1000 Manila, Philippines Tel. no. (+63 2) 85288001 Fax. no. (+63 2) 85211036, 85260279 wproepidata@who.int

Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 3 AMERICAN SAMOA Total population (2020) 55 197 Births (2011) 1 287 Surviving infants (2011) 1 278 Urban population (2020) 90% HepB3 introduced nationwide 1986-1987 HepB birth dose introduced 1991 Current schedule 0, 1 month, 12 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1990 National 3–4 years 95 not reported 82% not reported Mahoney Pac Hth Dialog 1996 1995 National 7-8 years 432 75% 91% not reported Bialek ISVHLD P351 2006 1996 National 7-8 years 435 not reported 87% not reported Mahoney Pac Hth Dialog 1996 2016 National 24-35 months 1180 97% 82% 85% MMWR May 25, 2018 / 67(20);579–584 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1991 Tutuila 3-4 years Community based 93 2.2% Mahoney JID 2009 1995 National 7-8 years Community based 432 0.5% Bialek ISVHLD P351 2006 2011 National 6 years School based 562 0.2% Govt American Samoa 2012 Status of verifying prevalence targets Verification started: February 2013 Decision: <1% in children Decision date: October 2014 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3

4 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification AUSTRALIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2007 National 12 months 280 874 not reported 94% 92% From National Health Insurance covering 99% of population Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2002 National 1-9 years Hospital based 249 0.4% (0.0% - 2.2%) Gidding Vaccine 2007 Total population (2020) 25 499 881 Births (2020) 318 478 Surviving infants (2020) 317 554 Urban population (2020) 86% HepB3 introduced nationwide 2000 HepB birth dose introduced 2000 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-Hib-HepB-IPV Verification started: June 2012 Decision: <1% in children Decision date: December 2012 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF’s Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank’s World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t s HepB3 Timely HepB BD *

Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 5 BRUNEI DARUSSALAM Total population (2020) 437 483 Births (2020) 6 156 Surviving infants (2020) 6 110 Urban population (2020) 80% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-Hib-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2011 National 8-9 years School based 4 513 0.09% MoH Brunei 2012 Status of verifying prevalence targets Verification started: March 2013 Decision: <1% in children Decision date: June 2013 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD *

Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 7 CHINA Total population (2020) 1 439 323 774 Births (2020) 16 233 446 Surviving infants (2020) 16 086 657 Urban population (2020) 61% HepB3 introduced nationwide 1992 HepB birth dose introduced 1992 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2004 National 12-23 months 171 188 not reported 85% not reported The National EPI Evaluation Report 2004 (Confirmation method by card only); 90% HepB3 by 12 months 2006 National 1 year 3636 93% 83% not reported Liang JID 2009; 2005 birth cohort 2008 National 12-23 months 9762 not reported 93% 91% Analysis Report of National Health Services Survey in China Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2006 National 1-4 years Community based 16 376 1.0% (0.8% - 1.2%) Liang JID 2009 2006 National 5 years Community based 2215 1.1% (0.4% - 1.8%) Liang JID 2009 2006 National 6 years Community based 2356 0.9% (0.4% - 1.5%) Liang JID 2009 2012 National 1-4 years Community based 5474 0.5% (0.3% - 0.7%) Yonghao International Journal of Infectious Diseases 2015 2012 National 5-9 years Community based 4407 0.7% (0.5% - 1.0%) Yonghao International Journal of Infectious Diseases 2015 2012 National 10-14 years Community based 3326 1.2% (0.8% - 1.6%) Yonghao International Journal of Infectious Diseases 2015 2014 National 1-4 years Community based 12 681 0.3% (0.2% - 0.5%) Cui FQ Emerging Infectious Diseases 2017 2014 National 5-14 years Community based 9738 0.9% (0.7% - 1.3%) Cui FQ Emerging Infectious Diseases 2017 2014 National 15-29 years Community based 9294 4.4% (3.8% - 5.1%) Cui FQ Emerging Infectious Diseases 2017 Status of verifying prevalence targets Verification started: February 2012 Decision: <1% in children Decision date: June 2012 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. Hepatitis B serological surveys 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD *

10 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification COOK ISLANDS Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2012 7 of 11 islands 6 years School based 269 0% Patel Vaccine 2016 Total population (2020) 17 564 Births (2019) 218 Surviving infants (2019) 218 Urban population (2020) 75% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 6 weeks, 3 months, 5 months HepB3 type DTP-Hib-HepB Verification started: January 2013 Decision: <1% in children Decision date: October 2013 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD

Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 11 FIJI Total population (2020) 896 444 Births (2020) 18 472 Surviving infants (2020) 18 112 Urban population (2020) 59% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1999 National 12-23 months not reported not reported 94% 92% Fiji National EPI Survey 2005 National 12-23 months 630 not reported 92% 83% Fiji Immunization Coverage Survey Report 2008 National 15-26 months 1200 86% 99% 99% Fiji National Immunisation Coverage Survey 2013 National not reported not reported not reported not reported 91% WHO-UNICEF Joint Reporting Form (Data for 2014) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998 Large Towns 12-24 months Hospital based 285 0.7% Wilson Vaccine 2000 2008 Sub-national 6 months-5 years Community based 428 0% WHO:RS/2009/GE/23(JPN) Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization HepB3 coverage at national and district level are inconsistent due to different data sources used by Fiji. *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD *

Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 19 FEDERATED STATES OF MICRONESIA Total population (2020) 115 021 Births (2020) 2 601 Surviving infants (2020) 2 544 Urban population (2020) 21% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1989 National 2 years 16 391 not reported 84% not reported Manea PH Reports 1992 1992 Chuuk 2 years 544 not reported 40% not reported Mahoney Pac Hth Dialog 1996 1994 Pohnpei 3-4 years 364 not reported 82% not reported Mahoney Pac Hth Dialog 1996 2000 Chuuk 2-6 years 365 50% 87% not reported Bialek ISVHLD P351 2006 2005 Pohnpei 2-9 years 478 87% 90% not reported Bialek Ped Infect Dis 2010 2005 National 2-9 years 432 75% 91% not reported Bialek ISVHLD P351 2006 2016 Chuuk 24-25 months 1218 54% 78% 72% MMWR May 25, 2018 / 67(20);579–584 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2005 Chuuk 2-6 years Hospital based 362 2.5% Bialek PID 2010 2005 Pohnpei 2-6 years Hospital based 478 1.5% Bialek PID 2010 2016 National 5-6 years School based 2106 0.3% (0.1% - 0.5%) 2017 MoH Federated States of Micronesia Status of verifying prevalence targets Verification started: October 2017 Decision: <1% in children Decision date: March 2018 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. Hepatitis B serological surveys 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD *

Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 13 GUAM Total population (2020) 168 783 Births (2020) 2 756 Surviving infants (2020) 2 734 Urban population (2020) 95% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 1-2 months, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2015 National 6 years School based 1484 0.0% Guam DoH & Social Services 2015 Status of verifying prevalence targets Verification started: October 2015 Decision: <1% in children Decision date: June 2016 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD

8 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification HONG KONG SAR (CHINA) Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2009 National 2-5 years 6248 not reported ≥99.5% >99.8% MoH Hong Kong 2011 2015 National 2-5 years not reported >95.0% >95.0% >95.0% WHO-UNICEF Joint Reporting Form (data for 2017) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2006 National 1-4 years Laboratory based 196 1% MoH Hong Kong 2011 2009 National 12-15 years School based 1913 0.8% (0.4% - 1.2%) MoH Hong Kong 2011 Total population (2020) 7 496 988 Births (2020) 82 839 Surviving infants (2020) 82 736 Urban population (2020) 100% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Verification started: February 2011 Decision: <1% in children Decision date: July 2011 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD

14 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification JAPAN Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1989 Okinawa 1-4 years School based 1529 0.1% Hayashi Int J Epi 1990 1995-1996 National 16-19 years Blood Donors 107 879 0.4% (0.4% - 0.5%) Furusyo AMTM 1998 1995-2000 National 16-19 years Blood Donors 582 415 0.23% (0.22% - 0.24%) Tanaka Intervirol 2004 2009 Iwate prefecture 5-9 years School based 17 363 0.0% (0.00%-0.04%) Tanaka Intervirol 2011 2005-2010 National 4-15 years Serum reference bank 3000 0.17% (0.0-0.41) Kiyohara T Vaccine 2015 Total population (2020) 126 476 458 Births (2020) 908 919 Surviving infants (2020) 907 427 Urban population (2020) 92% HepB3 introduced nationwide October 2016 HepB birth dose introduced If born to HBsAg+ mothers Current schedule 2 months, 3 months, 7 months HepB3 type Monovalent Verification started: pending Decision: n.a. Decision date: n.a. Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD

6 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification CAMBODIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2005 National 12-23 months 1517 not reported not reported 78% DHS Survey 2009 National 12-23 months 1068 61% not reported 56% Cambodia Socio-Economic Survey 2009 (confirmation method only by card) 2010 National 12-23 months 1614 73% 84% 84% DHS Survey:HepB BD 73%, HepB3 85%, DTP3 85% by 12 months 2014 National 12-23 months 1460 83% 84% 84% DHS Survey:HepB BD 83%, HepB3 82%, DTP3 82% by 12 months Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2001 Kg Chhnang 9-17 months Hospital based 900 2.7% Report MoH/PATH/AIHI 2006 National 5 years Community based 1 558 3.5% (2.4% - 4.8%) Soeung AMTH 2009 2011 Urban, Rural, Remote 4-5 years Community based 2 429 0.3%, 1.4%, 3.5% Mao Vaccine 2013 2017 National 5-6 years Community based 2 520 0.6% (0.3% - 1.0%) Cambodia MOH 2017 preliminary data 2017 National 5-7 years Cross-sectional survey 2 520 0.56% Ork Vaccine 2019 Total population (2020) 16 718 971 Births (2020) 360 189 Surviving infants (2020) 352 521 Urban population (2020) 24% HepB3 introduced nationwide 2005 HepB birth dose introduced 2005 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Verification started: January 2018 Decision: <1% in children Decision date: June 2018 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD *

Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 15 KIRIBATI Total population (2020) 119 446 Births (2020) 3 233 Surviving infants (2020) 3 104 Urban population (2020) 57% HepB3 introduced nationwide 1995 HepB birth dose introduced 1990 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2009 National 48-59 months 181 not reported not reported 32% DHS Survey; by 12 months 2009 National 36-47 months 200 not reported not reported 42% DHS Survey; by 12 months 2009 National 24-35 months 202 not reported not reported 50% DHS Survey; by 12 months 2009 National 12-23 months 233 not reported 61% 61% DHS Survey: HepB3 58%, DTP3 58% by 12 months Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998 Large Towns 12-24 months Hospital based 156 3.8% Wilson Vaccine 2000 2014 National 5-9 years Community based 1249 3.3% (2.4% - 4.6%) Patel Vaccine 2016 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD *

Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 29 REPUBLIC OF KOREA Total population (2020) 51 269 183 Births (2020) 358 793 Surviving infants (2020) 358 115 Urban population (2020) 82% HepB3 introduced nationwide 1983 HepB birth dose introduced 1983 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2008 National 0-6 years 1026 100% 93% 95% CDC Korea; provided during 2012 TAG 2009 National 19-35 months not reported not reported 99% 99% 2009 Korea National Immunization Survey (Confirmation method NA) 2011 National 0-3 years 7040 99% 98% 93% CDC Korea; provided during 2012 TAG Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2005 National 10-14 years Community based 594 0.2% (0.0% - 0.6%) CDC Korea 2008 2007 National 4-6 years Hospital based 2920 0.2% (0.0% - 0.4%) CDC Korea 2008 2014 National 10-18 years Community based 510 0.1% KNHANES 2014 Status of verifying prevalence targets Verification started: January 2008 Decision: <1% in children Decision date: June 2008 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD

16 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification LAO PEOPLE’S DEMOCRATIC REPUBLIC Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2006 National 12-23 months 828 not reported not reported 41% Lao PDR Multiple Indicator Cluster Survey 2006 Final Report; DTP3 32% by 12 months 2011-2012 National 12-23 months 2141 37% 56% 56% Lao Social Indicator Survey (LSIS), (MICS / DHS Survey): HepB BD 37%, HepB3 52%, DTP3 52% by 12 months 2015 National 12-23 months 5981 72% 81% 81% National Immunization Survey Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2012 National 5-9 years Community based 965 1.7% (0.8% - 2.6%) Xeuatvongsa PloS ONE 2014 Total population (2020) 7 275 556 Births (2020) 164 753 Surviving infants (2020) 158 882 Urban population (2020) 36% HepB3 introduced nationwide 2001 HepB birth dose introduced ~2004 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Verification started: pending Decision: n.a. Decision date: n.a. Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD *

Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 9 MACAO SAR (CHINA) Total population (2020) 649 342 Births (2020) 6 961 Surviving infants (2019) 6 944 Urban population (2020) 100% HepB3 introduced nationwide 1984 HepB birth dose introduced 1989 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2003 National 6-9 years School based 437 0% (0% - 0.7%) MoH Macao 2008 Status of verifying prevalence targets Verification started: April 2008 Decision: <1% in children Decision date: August 2008 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD

18 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification MARSHALL ISLANDS Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2006 National 0-24 months 115 not reported 86% 65% RMI Community Survey2006: confirmation method by card only 2007 Majuro, Ebeye 5-9 years 331 49% 93% not reported Bialek Ped Infect Dis 2010 2007 National not reported 214 not reported not reported 17% (for age 48-59M); 32% (for age 36-47M) DHS Survey 2007: DTP3 by 12 months 2007 National 24-35 months 207 not reported not reported 32% DHS Survey 2007: DTP3 by 12 months 2007 National 12-23 months 249 not reported not reported 48% DHS Survey; DTP3 38% by 12 months 2016 National 24-35 months 1312 87% 76% 72% MMWR May 25, 2018 / 67(20);579–584 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2007 Majuro, Ebeye 5-9 years School based 331 1.8% (0.4% - 3.3%) Bialek PID 2010 2016 National 5-6 years School based 1148 1.2% (0.6% - 1.9%) 2018 MoH Marshall Islands Total population (2020) 59 194 Births (2019) 1 090 Surviving infants (2019) 1 068 Urban population (2020) 70% HepB3 introduced nationwide 1990s HepB birth dose introduced 1998 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-HepB-IPV Verification started: pending Decision: n.a. Decision date: n.a. Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD

20 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2001 National 12-23 months 1255 not reported not reported 89% Mongolia, Child and Development survey-2000 (MICS-2), 2001 2004 National 4-6 years 5894 95% 73% not reported MoH Mongolia 2011 2004 National 8 years 1145 65% 60% not reported Davaalkham J Epid 2007 2005 National 12-23 months 724 not reported not reported 93% Mongolia Child and Development 2005 Survey (MICS-3): DTP3-92% by 12M 2010 National 12-23 months 944 97% not reported 92% MICS : HepB BD 96.7% by 12M; DPT3 92.1% by 12M 2013 National 12-23 months 1180 99% 98% 98% Mongolia Social Indicator Sample Survey: HepB BD 93.1%, HepB3 92.5%, DTP3 92.5% by 12M 2013 National 24-35 months 1236 97% 96% 96% Mongolia Social Indicator Sample Survey :HepB BD 86%, HepB3 84.2%, DTP3 84.2% by 12M Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2004 National 7-12 years School based 1145 5.2% Davaalkham PI 2007 2009 National 4 years Community based 5894 0.5% MoH Mongolia 2011 Total population (2020) 3 278 292 Births (2020) 73 755 Surviving infants (2020) 72 552 Urban population (2020) 67% HepB3 introduced nationwide 1991 HepB birth dose introduced 1991 Current schedule 0, 2 months, 3 months, 4 months HepB3 type DTP-Hib-HepB Verification started: April 2012 Decision: <1% in children Decision date: July 2012 Status of verifying prevalence targets Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. MONGOLIA 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD *

Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 25 NORTHERN MARIANA ISLANDS, COMMONWEALTH OF THE Total population (2020) 57 557 Births (2019) 909 Surviving infants (2019) 905 Urban population (2020) 88% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 6 weeks, 4 months, 6 months HepB3 type DTP-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1995 National 3-4 years 200 not reported 94% not reported Mahoney Pac Hth Dialog 1996 2005 National 19-35 months 295 100% 94% not reported 2016 National 24-35 months 1140 98% 62% 60% MMWR May 25, 2018 / 67(20);579–584 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1994 Saipan 3-4 years Health facility 200 0.5% Durand Pac Hlth Dial 1996 2014 National 6 years School based 804 0.0% CNMI Healthcare Corp. 2015 Status of verifying prevalence targets Verification started: December 2015 Decision: <1% in children Decision date: April 2017 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD

Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2020 Districts by coverage categories Neonatal deliveries Hepatitis B serological surveys WHO verification 17 MALAYSIA Total population (2020) 32 365 998 Births (2020) 531 804 Surviving infants (2020) 528 868 Urban population (2020) 78% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1997-2007 National 6-9 years School based 193 717 0.40% MoH Malaysia 2011 2003 National 7 years School based 12 269 0.40% Ng Med Microb Imm 2005 2007 National 7-9 years Community based 1735 0.30% MoH Malaysia 2008 2009 National 9 years School based 2938 0.2% (0% - 0.3%) MoH Malaysia 2011 2009 National 10 years School based 3265 0.4% (0.2% - 0.6%) MoH Malaysia 2011 Status of verifying prevalence targets Verification started: March 2011 Decision: <1% in children Decision date: July 2011 Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 Women aged 15–49 Women aged 15–19 In health facility P r o p o r t i o n o f d e l i v e r i e s Skilled birth attendant 0 20 40 60 80 100 2016 2017 2018 2019 2020 V a c c i n a t i o n C o v e r a g e ( % ) Timely HepB BD Any HepB BD HepB3 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D i s t r i c t HepB3 Timely HepB BD *